Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Application of total X-Ray fluorescence to gunshot residue determination.

Sarapura P, Gonzalez MF, Gonzalez F, Morzan E, Cerchietti L, Custo G.

Appl Radiat Isot. 2019 Aug 7;153:108841. doi: 10.1016/j.apradiso.2019.108841. [Epub ahead of print]

PMID:
31419745
2.

Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.

Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, Wang L, Hu J, Jing H, Chen Z, Jain N, Duy C, Mistry SJ, Cerchietti L, Cross JR, Cantley LC, Green MR, Lin H, Melnick AM.

Cancer Cell. 2019 Jun 10;35(6):916-931.e9. doi: 10.1016/j.ccell.2019.05.002.

PMID:
31185214
3.

Thyroid hormones induce doxorubicin chemosensitivity through enzymes involved in chemotherapy metabolism in lymphoma T cells.

Díaz Flaqué MC, Cayrol MF, Sterle HA, Del Rosario Aschero M, Díaz Albuja JA, Isse B, Farías RN, Cerchietti L, Rosemblit C, Cremaschi GA.

Oncotarget. 2019 Apr 30;10(32):3051-3065. doi: 10.18632/oncotarget.26890. eCollection 2019 Apr 30.

4.

BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress.

Fernando TM, Marullo R, Pera Gresely B, Phillip JM, Yang SN, Lundell-Smith G, Torregroza I, Ahn H, Evans T, Győrffy B, Privé GG, Hirano M, Melnick AM, Cerchietti L.

Cancer Discov. 2019 May;9(5):662-679. doi: 10.1158/2159-8290.CD-17-1444. Epub 2019 Feb 18.

PMID:
30777872
5.

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP.

Blood. 2018 Nov 8;132(19):2016-2025. doi: 10.1182/blood-2018-07-859769. Epub 2018 Sep 4.

6.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM.

Cancer Res. 2018 May 15;78(10):2747-2759. doi: 10.1158/0008-5472.CAN-17-1900. Epub 2018 Mar 20.

7.

Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.

Pera B, Krumsiek J, Assouline SE, Marullo R, Patel J, Phillip JM, Román L, Mann KK, Cerchietti L.

EBioMedicine. 2018 Feb;28:80-89. doi: 10.1016/j.ebiom.2018.01.014. Epub 2018 Jan 31.

8.

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.

Leuk Lymphoma. 2018 Jan;59(1):256-258. doi: 10.1080/10428194.2017.1323270. Epub 2017 Jun 2. No abstract available.

PMID:
28573908
9.

Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.

Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, Kwon JA, Meydan C, Perales-Paton J, Arshi A, Gönen M, Famulare C, Patel M, Paietta E, Tallman MS, Lu Y, Glass J, Garret-Bakelman FE, Melnick A, Levine R, Al-Shahrour F, Järås M, Hacohen N, Hwang A, Garippa R, Lengner CJ, Armstrong SA, Cerchietti L, Cowley GS, Root D, Doench J, Leslie C, Ebert BL, Kharas MG.

Nat Genet. 2017 Jun;49(6):866-875. doi: 10.1038/ng.3854. Epub 2017 Apr 24.

10.

Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers.

Deb D, Rajaram S, Larsen JE, Dospoy PD, Marullo R, Li LS, Avila K, Xue F, Cerchietti L, Minna JD, Altschuler SJ, Wu LF.

Cancer Res. 2017 Jun 1;77(11):3070-3081. doi: 10.1158/0008-5472.CAN-15-3052. Epub 2017 Apr 4.

11.

BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.

Valls E, Lobry C, Geng H, Wang L, Cardenas M, Rivas M, Cerchietti L, Oh P, Yang SN, Oswald E, Graham CW, Jiang Y, Hatzi K, Agirre X, Perkey E, Li Z, Tam W, Bhatt K, Leonard JP, Zweidler-McKay PA, Maillard I, Elemento O, Ci W, Aifantis I, Melnick A.

Cancer Discov. 2017 May;7(5):506-521. doi: 10.1158/2159-8290.CD-16-1189. Epub 2017 Feb 23.

12.

Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, Zhang T, Cremaschi G, Gray NS, Cerchietti L.

Nat Commun. 2017 Feb 20;8:14747. doi: 10.1038/ncomms14747. No abstract available.

13.
14.

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.

Cayrol F, Praditsuktavorn P, Fernando TM, Kwiatkowski N, Marullo R, Calvo-Vidal MN, Phillip J, Pera B, Yang SN, Takpradit K, Roman L, Gaudiano M, Crescenzo R, Ruan J, Inghirami G, Zhang T, Cremaschi G, Gray NS, Cerchietti L.

Nat Commun. 2017 Jan 30;8:14290. doi: 10.1038/ncomms14290.

15.

Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.

Du W, Goldstein R, Jiang Y, Aly O, Cerchietti L, Melnick A, Elemento O.

Cancer Res. 2017 Apr 15;77(8):1818-1830. doi: 10.1158/0008-5472.CAN-16-0476. Epub 2017 Jan 27.

16.

DNA Methylation-Based Biomarkers.

Cerchietti L, Melnick A.

J Clin Oncol. 2017 Mar;35(7):793-795. doi: 10.1200/JCO.2016.71.0616. Epub 2017 Jan 23. No abstract available.

PMID:
28113009
17.

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.

Boi M, Todaro M, Vurchio V, Yang SN, Moon J, Kwee I, Rinaldi A, Pan H, Crescenzo R, Cheng M, Cerchietti L, Elemento O, Riveiro ME, Cvitkovic E, Bertoni F, Inghirami G; AIRC 5xMille Consortium ‘Genetics-Driven Targeted Management of Lymphoid Malignancies’.

Oncotarget. 2016 Nov 29;7(48):79637-79653. doi: 10.18632/oncotarget.12876.

18.

The epichaperome is an integrated chaperome network that facilitates tumour survival.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G.

Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807. Epub 2016 Oct 5.

19.

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, Shaknovich R, Vanommeslaeghe K, Cheng H, Liang D, Cho HJ, Abbott J, Tam W, Du W, Leonard JP, Elemento O, Cerchietti L, Cierpicki T, Xue F, MacKerell AD Jr, Melnick AM.

J Clin Invest. 2016 Sep 1;126(9):3351-62. doi: 10.1172/JCI85795. Epub 2016 Aug 2.

20.

Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.

Pera B, Tang T, Marullo R, Yang SN, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J, Cerchietti L, Martin P.

Clin Epigenetics. 2016 Jul 22;8:79. doi: 10.1186/s13148-016-0245-y. eCollection 2016.

21.

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.

Marullo R, Rutherford SC, Leonard JP, Cerchietti L.

Cell Cycle. 2016 Sep;15(17):2241-7. doi: 10.1080/15384101.2016.1207839. Epub 2016 Jul 15.

22.

Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.

Dupéré-Richer D, Kinal M, Pettersson F, Emond A, Calvo-Vidal MN, Nichol JN, Guilbert C, Plourde D, Klein Oros K, Nielsen TH, Ezponda T, Licht JD, Johnson NA, Assouline S, Cerchietti L, Miller WH Jr, Mann KK.

Leuk Lymphoma. 2017 Jan;58(1):218-221. Epub 2016 May 17. No abstract available.

PMID:
27185211
23.

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.

Dupont T, Yang SN, Patel J, Hatzi K, Malik A, Tam W, Martin P, Leonard J, Melnick A, Cerchietti L.

Oncotarget. 2016 Jan 19;7(3):3520-32. doi: 10.18632/oncotarget.6513.

24.

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, Machiorlatti R, Elemento O, Inghirami G, Melnick A, Borden KL, Cerchietti L.

Blood. 2016 Feb 18;127(7):858-68. doi: 10.1182/blood-2015-05-645069. Epub 2015 Nov 24.

25.

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A.

J Clin Invest. 2015 Nov 3;125(12):4559-71. doi: 10.1172/JCI80714.

26.

Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.

Tian YF, Ahn H, Schneider RS, Yang SN, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A.

Biomaterials. 2015 Dec;73:110-9. doi: 10.1016/j.biomaterials.2015.09.007. Epub 2015 Sep 11.

27.

High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.

Pera B, Calvo-Vidal MN, Ambati S, Jordi M, Kahn A, Díaz JF, Fang W, Altmann KH, Cerchietti L, Moore MAS.

Cancer Lett. 2015 Nov 1;368(1):97-104. doi: 10.1016/j.canlet.2015.07.038. Epub 2015 Aug 12.

28.

Ex vivo engineered immune organoids for controlled germinal center reactions.

Purwada A, Jaiswal MK, Ahn H, Nojima T, Kitamura D, Gaharwar AK, Cerchietti L, Singh A.

Biomaterials. 2015 Sep;63:24-34. doi: 10.1016/j.biomaterials.2015.06.002. Epub 2015 Jun 3.

29.

Epigenomic evolution in diffuse large B-cell lymphomas.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R, Melnick AM, Inghirami GG, Tam W, Elemento O.

Nat Commun. 2015 Apr 20;6:6921. doi: 10.1038/ncomms7921.

30.

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Abate F, Todaro M, van der Krogt JA, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A, Novero D, Gaudiano M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal J, Chan WC, Shultz LD, Kwee I, Piva R, Wlodarska I, Rabadan R, Bertoni F, Inghirami G; European T-cell Lymphoma Study Group.

Leukemia. 2015 Jun;29(6):1390-401. doi: 10.1038/leu.2014.347. Epub 2014 Dec 23.

31.

Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells.

Cayrol F, Díaz Flaqué MC, Fernando T, Yang SN, Sterle HA, Bolontrade M, Amorós M, Isse B, Farías RN, Ahn H, Tian YF, Tabbò F, Singh A, Inghirami G, Cerchietti L, Cremaschi GA.

Blood. 2015 Jan 29;125(5):841-51. doi: 10.1182/blood-2014-07-587337. Epub 2014 Dec 8.

32.

Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.

Izzo F, Mercogliano F, Venturutti L, Tkach M, Inurrigarro G, Schillaci R, Cerchietti L, Elizalde PV, Proietti CJ.

Breast Cancer Res. 2014 Dec 6;16(6):491. doi: 10.1186/s13058-014-0491-x.

33.

Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials.

Nielsen TH, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AM, Oros KK, Krumsiek J, Crump M, Morin RD, Cerchietti L, Johnson NA, Petrogiannis-Haliotis T, Miller WH Jr, Assouline SE, Mann KK.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2688-93. doi: 10.1158/1055-9965.EPI-14-0549.

34.

Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications.

Patel RG, Purwada A, Cerchietti L, Inghirami G, Melnick A, Gaharwar AK, Singh A.

Cell Mol Bioeng. 2014 Sep 1;7(3):394-408.

35.

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.

Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN.

Oncotarget. 2014 Jul 30;5(14):5637-50.

36.

Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer.

Rodina A, Taldone T, Kang Y, Patel PD, Koren J 3rd, Yan P, DaGama Gomes EM, Yang C, Patel MR, Shrestha L, Ochiana SO, Santarossa C, Maharaj R, Gozman A, Cox MB, Erdjument-Bromage H, Hendrickson RC, Cerchietti L, Melnick A, Guzman ML, Chiosis G.

ACS Chem Biol. 2014 Aug 15;9(8):1698-705. doi: 10.1021/cb500256u. Epub 2014 Jun 17.

37.

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.

Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL.

Nature. 2014 Jul 3;511(7507):90-3. doi: 10.1038/nature13283. Epub 2014 May 28.

38.

The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.

Walker SR, Liu S, Xiang M, Nicolais M, Hatzi K, Giannopoulou E, Elemento O, Cerchietti L, Melnick A, Frank DA.

Oncogene. 2015 Feb 26;34(9):1073-82. doi: 10.1038/onc.2014.61. Epub 2014 Mar 24.

39.

Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury.

Irmady K, Jackman KA, Padow VA, Shahani N, Martin LA, Cerchietti L, Unsicker K, Iadecola C, Hempstead BL.

J Neurosci. 2014 Feb 26;34(9):3419-28. doi: 10.1523/JNEUROSCI.1982-13.2014.

40.

Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.

Cerchietti L, Leonard JP.

Hematology Am Soc Hematol Educ Program. 2013;2013:591-5. doi: 10.1182/asheducation-2013.1.591. Review.

PMID:
24319236
41.

Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?

Cerchietti L, Melnick A.

Expert Rev Hematol. 2013 Aug;6(4):343-5. doi: 10.1586/17474086.2013.826928. No abstract available.

42.

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A, Cerchietti L.

Cancer Discov. 2013 Sep;3(9):1002-19. doi: 10.1158/2159-8290.CD-13-0117. Epub 2013 Aug 16.

43.

Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E.

Blood. 2013 Oct 17;122(16):2837-47. doi: 10.1182/blood-2013-01-479972. Epub 2013 Aug 13.

44.

A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.

Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM, Kormaksson M, MacKerell AD Jr, Xue F, Mason CE, Hiebert SW, Prive GG, Cerchietti L, Bardwell VJ, Elemento O, Melnick A.

Cell Rep. 2013 Aug 15;4(3):578-88. doi: 10.1016/j.celrep.2013.06.016. Epub 2013 Aug 1.

45.

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD, Wong KK, Cerchietti L, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, Melnick AM.

Cancer Cell. 2013 May 13;23(5):677-92. doi: 10.1016/j.ccr.2013.04.011.

46.

The metabolism of lymphomas.

Calvo-Vidal MN, Cerchietti L.

Curr Opin Hematol. 2013 Jul;20(4):345-54. doi: 10.1097/MOH.0b013e3283623d16. Review.

PMID:
23673340
47.

Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.

Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M, Geng H, Leonard JP, Melnick A, Cerchietti L, Hajjar KA.

Blood. 2013 Jun 27;121(26):5192-202. doi: 10.1182/blood-2013-03-490763. Epub 2013 Apr 30.

48.

Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.

De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM, Cerchietti L, Gascoyne RD, Melnick A, Michor F.

PLoS Genet. 2013;9(1):e1003137. doi: 10.1371/journal.pgen.1003137. Epub 2013 Jan 10.

49.

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, Wu H, Melnick A.

Cancer Cell. 2012 Dec 11;22(6):812-24. doi: 10.1016/j.ccr.2012.11.003.

50.

The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.

Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai LJ, Leblanc M, Diehl C, Cerchietti L, Miller YI, Witztum JL, Melnick AM, Dent AL, Tangirala RK, Evans RM.

Cell Metab. 2012 Apr 4;15(4):554-62. doi: 10.1016/j.cmet.2012.02.012. Epub 2012 Mar 29.

Supplemental Content

Loading ...
Support Center